Cat. No. 3409
Alternative Name: BMS 189453
Chemical Name: 4-[(1E)-2-(5,6-Dihydro-5,5-dimethyl
Biological ActivitySynthetic retinoid. Retinoic acid receptor β (RARβ) agonist in vivo; RARα and RARγ antagonist in vitro. Inhibits breast cell proliferation by inducing active transforming growth factor β (TGFβ) and causes G1 arrest.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Monteiro et al (2009) Commitment of mouse embryonic stem cells to the adipocyte lineage requires retinoic acid receptor beta and active GSK3. Stem Cells Dev. 18 457. PMID: 18690793.
Yang et al (2001) The retinoic acid receptor antagonist, BMS543, inhibits normal breast cell growth by inducing active TGFB and causing cell cycle arrest. Oncogene 20 8025. PMID: 11753686.
Chen et al (1995) RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation. EMBO J. 14 1187. PMID: 7720709.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses BMS 453 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: BMS 453, supplier, BMS453, retinoic, acid, receptors, RARβ, RARα, RARγ, RARalpha, RARbeta, RARgamma, RARa, RARb, RARg, agonists, antagonists, BMS189453, Tocris Bioscience, Retinoic Acid Receptor products
Find multiple products by catalog number
New Products in this Area
Synthetic retinoid; induces differentiation of stem cellsSI-2 hydrochloride
Steroid receptor coactivator 3 (SRC-3) inhibitorSR 0987
T cell-specific RORγ (RORγt) agonistWAY 252623
Potent LXR agonistSR 9009
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.